{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:23:13Z","timestamp":1790392993547,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"am","delay-in-days":370,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.therap.2018.09.071","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T13:22:01Z","timestamp":1538572921000},"page":"407-419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact des benzodiaz\u00e9pines sur les fonctions cognitives et le risque de d\u00e9mence. Revue des arguments de causalit\u00e9 issus des \u00e9tudes observationnelles"],"prefix":"10.1016","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5494-5873","authenticated-orcid":false,"given":"Maryse","family":"Lapeyre-Mestre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.therap.2018.09.071_bib0240","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/pds.4123","article-title":"Trends in incident use of benzodiazepines and Z-drugs in France from 2006\u00a0to 2012: a population-based study","volume":"26","author":"Benard-Laribiere","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"10.1016\/j.therap.2018.09.071_bib0245","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1016\/j.euroneuro.2015.07.006","article-title":"Benzodiazepines and risk of death: results from two large cohort studies in France and UK","volume":"25","author":"Palmaro","year":"2015","journal-title":"Eur Neuropsychopharm"},{"issue":"2","key":"10.1016\/j.therap.2018.09.071_bib0250","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0031-6997(25)06840-1","article-title":"Structure and pharmacology of gamma-aminobutyric acid(a) receptor subtypes","volume":"47","author":"Sieghart","year":"1995","journal-title":"Pharmacol Rev"},{"issue":"4","key":"10.1016\/j.therap.2018.09.071_bib0255","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.tins.2011.01.004","article-title":"Hooked on benzodiazepines: GABA(A) receptor subtypes and addiction","volume":"34","author":"Tan","year":"2011","journal-title":"Trends Neurosci"},{"issue":"5","key":"10.1016\/j.therap.2018.09.071_bib0260","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S0006-3223(99)00061-X","article-title":"Altered GABA neurotransmission and prefrontal cortical dysfunction in schizophrenia","volume":"46","author":"Lewis","year":"1999","journal-title":"Biol Psychiat"},{"issue":"7","key":"10.1016\/j.therap.2018.09.071_bib0265","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.tins.2004.05.008","article-title":"Regulation of neocortical interneuron development and the implications for neurodevelopmental disorders","volume":"27","author":"Levitt","year":"2004","journal-title":"Trends Neurosci"},{"issue":"12","key":"10.1016\/j.therap.2018.09.071_bib0270","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s40266-016-0414-x","article-title":"A review of adverse outcomes associated with psychoactive drug use in nursing home residents with dementia","volume":"33","author":"Lapeyre-Mestre","year":"2016","journal-title":"Drugs Aging"},{"issue":"1","key":"10.1016\/j.therap.2018.09.071_bib0275","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pds.1038","article-title":"Drug related falls: a study in the French Pharmacovigilance database","volume":"14","author":"Souchet","year":"2005","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1\u20132","key":"10.1016\/j.therap.2018.09.071_bib0280","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.drugalcdep.2012.03.009","article-title":"Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France","volume":"126","author":"Pauly","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.therap.2018.09.071_bib0285","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0278-2626(03)00214-8","article-title":"Midazolam amnesia and retrieval from semantic memory: developing methods to test theories of implicit memory","volume":"53","author":"Hirshman","year":"2003","journal-title":"Brain Cogn"},{"issue":"4","key":"10.1016\/j.therap.2018.09.071_bib0290","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/BF02244257","article-title":"Comparison of the amnesic effects of midazolam and diazepam","volume":"103","author":"Hennessy","year":"1991","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.therap.2018.09.071_bib0295","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/BF00429206","article-title":"Memory and performance effects of single and 3-week administration of diazepam","volume":"73","author":"Ghoneim","year":"1981","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.therap.2018.09.071_bib0300","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0301-0511(86)90081-5","article-title":"Tranquillising memories: a review of the effects of benzodiazepines on human memory","volume":"23","author":"Curran","year":"1986","journal-title":"Biol Psychol"},{"issue":"1","key":"10.1016\/j.therap.2018.09.071_bib0305","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2165\/00023210-200418010-00004","article-title":"Cognitive effects of long-term benzodiazepine use: a meta-analysis","volume":"18","author":"Barker","year":"2004","journal-title":"CNS Drugs"},{"issue":"3","key":"10.1016\/j.therap.2018.09.071_bib0310","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0887-6177(03)00096-9","article-title":"Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis","volume":"19","author":"Barker","year":"2004","journal-title":"Arch Clin Neuropsychol"},{"key":"10.1016\/j.therap.2018.09.071_bib0315","doi-asserted-by":"crossref","first-page":"e6231","DOI":"10.1136\/bmj.e6231","article-title":"Benzodiazepine use and risk of dementia: prospective population based study","volume":"345","author":"Billioti de Gage","year":"2012","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.therap.2018.09.071_bib0320","doi-asserted-by":"crossref","first-page":"e0127836","DOI":"10.1371\/journal.pone.0127836","article-title":"Association between benzodiazepine use and dementia: a meta-analysis","volume":"10","author":"Zhong","year":"2015","journal-title":"Plos One"},{"issue":"3\u20134","key":"10.1016\/j.therap.2018.09.071_bib0325","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000454881","article-title":"Benzodiazepine use and risk of dementia in the elderly population: a systematic review and meta-analysis","volume":"47","author":"Islam","year":"2016","journal-title":"Neuroepidemiology"},{"issue":"7","key":"10.1016\/j.therap.2018.09.071_bib0330","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/JGP.0b013e3181a65210","article-title":"The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data","volume":"17","author":"Wu","year":"2009","journal-title":"Am J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.therap.2018.09.071_bib0335","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/JGP.0b013e3181e049ca","article-title":"Effect of benzodiazepine discontinuation on dementia risk","volume":"19","author":"Wu","year":"2011","journal-title":"Am J Geriatr Psychiatry"},{"issue":"10","key":"10.1016\/j.therap.2018.09.071_bib0340","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1136\/jech-2011-200314","article-title":"Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS)","volume":"66","author":"Gallacher","year":"2012","journal-title":"J Epidemiol Community Health"},{"key":"10.1016\/j.therap.2018.09.071_bib0345","doi-asserted-by":"crossref","first-page":"g5205","DOI":"10.1136\/bmj.g5205","article-title":"Benzodiazepine use and risk of Alzheimer's disease: case-control study","volume":"349","author":"Billioti de Gage","year":"2014","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.therap.2018.09.071_bib0350","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0895-4356(01)00453-X","article-title":"Benzodiazepine use and risk of dementia: a nested case-control study","volume":"55","author":"Lagnaoui","year":"2002","journal-title":"J Clin Epidemiol"},{"issue":"10","key":"10.1016\/j.therap.2018.09.071_bib0355","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s40264-015-0319-3","article-title":"Benzodiazepine use and risk of developing Alzheimer's disease or vascular dementia: a case-control analysis","volume":"38","author":"Imfeld","year":"2015","journal-title":"Drug Safe"},{"issue":"17","key":"10.1016\/j.therap.2018.09.071_bib0360","doi-asserted-by":"crossref","first-page":"e809","DOI":"10.1097\/MD.0000000000000809","article-title":"An increased risk of reversible dementia may occur after zolpidem derivative use in the elderly population: a population-based case-control study","volume":"94","author":"Shih","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"10.1016\/j.therap.2018.09.071_bib0365","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jalz.2015.10.006","article-title":"Benzodiazepine, psychotropic medication, and dementia: a population-based cohort study","volume":"12","author":"Shash","year":"2016","journal-title":"Alzheimers Dement"},{"issue":"4","key":"10.1016\/j.therap.2018.09.071_bib0370","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2515\/therapie\/2013037","article-title":"Pharmacoepidemiology studies: what levels of evidence and how can they be reached?","volume":"68","author":"Lapeyre-Mestre","year":"2013","journal-title":"Therapie"},{"issue":"5","key":"10.1016\/j.therap.2018.09.071_bib0375","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/(SICI)1099-1166(199705)12:5<567::AID-GPS552>3.0.CO;2-V","article-title":"Psychotropic drug use and cognitive decline among older men and women","volume":"12","author":"Dealberto","year":"1997","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"10.1016\/j.therap.2018.09.071_bib0380","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/00002093-199803000-00002","article-title":"Benzodiazepines may have protective effects against Alzheimer disease","volume":"12","author":"Fastbom","year":"1998","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"6","key":"10.1016\/j.therap.2018.09.071_bib0385","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/S0009-9236(98)90059-5","article-title":"Benzodiazepine use and cognitive function among community-dwelling elderly","volume":"64","author":"Hanlon","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.therap.2018.09.071_bib0390","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/00004714-200206000-00009","article-title":"Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study","volume":"22","author":"Paterniti","year":"2002","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"10.1016\/j.therap.2018.09.071_bib0395","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/gps.891","article-title":"Consumption of psychotropic medication in the elderly: a re-evaluation of its effect on cognitive performance","volume":"18","author":"Allard","year":"2003","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"10.1016\/j.therap.2018.09.071_bib0400","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/ageing\/afn277","article-title":"The risk of cognitive impairment in older community-dwelling women after benzodiazepine use","volume":"38","author":"Lagnaoui","year":"2009","journal-title":"Age Ageing"},{"issue":"10","key":"10.1016\/j.therap.2018.09.071_bib0405","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s00228-011-1047-y","article-title":"Impact of long-term benzodiazepine use on cognitive functioning in young adults: the VISAT cohort","volume":"67","author":"Boeuf-Cazou","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.therap.2018.09.071_bib0410","doi-asserted-by":"crossref","first-page":"e49113","DOI":"10.1371\/journal.pone.0049113","article-title":"Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study","volume":"7","author":"Chen","year":"2012","journal-title":"Plos One"},{"issue":"3","key":"10.1016\/j.therap.2018.09.071_bib0415","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.euroneuro.2012.05.004","article-title":"Chronic use of benzodiazepines and latent cognitive decline in the elderly: results from the Three-city study","volume":"23","author":"Mura","year":"2013","journal-title":"Eur Neuropsychopharmacol"},{"issue":"Suppl. 1","key":"10.1016\/j.therap.2018.09.071_bib0420","first-page":"21","article-title":"Benzodiazepines new use and long-term cognitive decline in elderly: a prospective cohort study","volume":"28","author":"Marchand","year":"2014","journal-title":"Fund Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.therap.2018.09.071_bib0425","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3233\/JAD-151006","article-title":"Regular benzodiazepine and z-substance use and risk of dementia: an analysis of German claims data","volume":"54","author":"Gomm","year":"2016","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.therap.2018.09.071_bib0430","doi-asserted-by":"crossref","first-page":"i90","DOI":"10.1136\/bmj.i90","article-title":"Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study","volume":"352","author":"Gray","year":"2016","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.therap.2018.09.071_bib0435","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1111\/jgs.15018","article-title":"The association between the use of zolpidem and the risk of Alzheimer's disease among older people","volume":"65","author":"Cheng","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.therap.2018.09.071_bib0440","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/jgs.14756","article-title":"PTSD, psychotropic medication use, and the risk of dementia among US veterans: a retrospective cohort study","volume":"65","author":"Mawanda","year":"2017","journal-title":"J Am Geriatr Soc"},{"issue":"5","key":"10.1016\/j.therap.2018.09.071_bib0445","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/psyg.12239","article-title":"Association between high cumulative dose of benzodiazepine in Chinese patients and risk of dementia: a preliminary retrospective case-control study","volume":"17","author":"Chan","year":"2017","journal-title":"Psychogeriatrics"},{"issue":"3","key":"10.1016\/j.therap.2018.09.071_bib0450","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40263-016-0404-x","article-title":"Benzodiazepine use and risk of developing Alzheimer's disease: a case-control study based on Swiss claims data","volume":"31","author":"Bi\u00e9try","year":"2017","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.therap.2018.09.071_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40263-015-0305-4","article-title":"The benzodiazepine-dementia disorders link: current state of knowledge","volume":"30","author":"Pariente","year":"2016","journal-title":"CNS Drugs"},{"issue":"4","key":"10.1016\/j.therap.2018.09.071_bib0460","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.bbrc.2015.01.022","article-title":"Midazolam inhibits the formation of amyloid fibrils and GM1\u00a0ganglioside-rich microdomains in presynaptic membranes through the gamma-aminobutyric acid A receptor","volume":"457","author":"Yamamoto","year":"2015","journal-title":"Biochem Biophys Res Commun"},{"issue":"9","key":"10.1016\/j.therap.2018.09.071_bib0465","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1017\/S0265021506000494","article-title":"Unchanged rat brain amyloid precursor protein levels after exposure to benzodiazepines in vivo","volume":"23","author":"K\u00e1lm\u00e1n","year":"2006","journal-title":"Eur J Anaesthesiol"},{"issue":"4","key":"10.1016\/j.therap.2018.09.071_bib0235","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jalz.2016.07.152","article-title":"Systematic evaluation of the associations between environmental risk factors and dementia: an umbrella review of systematic reviews and meta-analyses","volume":"13","author":"Bellou","year":"2017","journal-title":"Alzheimers Dement"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571830218X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059571830218X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:53:04Z","timestamp":1758567184000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059571830218X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S004059571830218X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2018.09.071","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact des benzodiaz\u00e9pines sur les fonctions cognitives et le risque de d\u00e9mence. Revue des arguments de causalit\u00e9 issus des \u00e9tudes observationnelles","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2018.09.071","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}